TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03166254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: -Pembrolizumab will be given intravenously over the course of 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: -Pembrolizumab will be given intravenously over the course of 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PV-01 vaccine
Description: -Generation of the vaccine is expected to take approximately 12 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PV-01 vaccine
Description: -Generation of the vaccine is expected to take approximately 12 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: -Surgical or core needle biopsy of an accessible site for DNA and RNA sequencing, immunological analysis, and generation of NEO-PV-01 vaccine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: -Surgical or core needle biopsy of an accessible site for DNA and RNA sequencing, immunological analysis, and generation of NEO-PV-01 vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: -NEO-PV-01 is combined with the adjuvant poly-ICLC prior to administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: -NEO-PV-01 is combined with the adjuvant poly-ICLC prior to administration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: -Peripheral blood mononuclear cells (PBMCs) for comprehensive immune system monitoring will be obtained from leukapheresis samples collected up to 7 days prior to initiation of NEO PV-01 vaccination and at 7 days (Week 20) following the first NEO-PV-01 booster vaccination.
Study: NCT03941574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. The excipients include 0.95 mg/mL citric acid (citric acid monohydrate), 4.56 mg/mL sodium citrate (sodium citrate dihydrate), 3.0 mg/mL sodium chloride, 30.0 mg/mL mannitol and 0.20 mg/mL polysorbate 80 (tween 80), with pH of 5.5.
Study: NCT03734159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
Study: NCT03166254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: -Peripheral blood mononuclear cells (PBMCs) for comprehensive immune system monitoring will be obtained from leukapheresis samples collected up to 7 days prior to initiation of NEO PV-01 vaccination and at 7 days (Week 20) following the first NEO-PV-01 booster vaccination.
Study: NCT00740103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semapimod
Description: 60 mg IV x 3 days q 6 - 8 weeks
Study: NCT03166254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples
Description: -Blood samples (80 mL) for immune monitoring will be obtained prior to study treatment and at Weeks 6, 14, 16, 24, 36, 48, 63, 75, 87, and 99.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples
Description: -Blood samples (80 mL) for immune monitoring will be obtained prior to study treatment and at Weeks 6, 14, 16, 24, 36, 48, 63, 75, 87, and 99.
Study: NCT03734159

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride 0.9%
Description: Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
Study: NCT01767389

Intervention type: OTHER
Intervention: The GLP-1 receptor agonist users
Description: The GLP-1 receptor agonist users are classified based on the receipt of a GLP-1 receptor agonist at the index date. GLP-1 receptor agonists included in this study are exenatide and liraglutide

Intervention type: OTHER
Intervention: DPP-4 inhibitor users
Description: DPP-4 inhibitor users are classified based on the receipt of a DPP-4 inhibitor prescription at the index date. The DPP-4 inhibitors included in this study are sitagliptin, saxagliptin, linagliptin, combination of sitagliptin and metformin (Janumet), and combination of sitagliptin and simvastatin (Juvisync)

Intervention type: OTHER
Intervention: Other ADA users
Description: Classes of ADA's other than GLP-1 receptor agonists and DPP-4 inhibitors will be included in the 'other ADA' exposure group
Study: NCT01818024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single IV dose of GSK2862277
Description: GSK2862277 solution available in a 40 mg vial for IV administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single IV dose of GSK2862277
Description: GSK2862277 solution available in a 40 mg vial for IV administration.
Study: NCT03188029

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: adrenocortical function
Description: Blood samples for cortisol dosage are performed and 24 hours after the sixth session. All blood samples are performed at 9 and collected in normal tube.~Blood samples for glycaemia, sodium, potassium and bicarbonates are performed at the same rate.
Study: NCT01271738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remove tumor only
Description: No additional margins (tissue) removed at the initial surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal of tumor and tissue
Description: 5 additional margins (tissue) removed at the time of surgery
Study: NCT01818024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single IV dose of GSK2862277
Description: GSK2862277 solution available in a 40 mg vial for IV administration.
Study: NCT04333173

Intervention type: PROCEDURE
Intervention: endovascular procedure
Description: Endovascular therapies for erectile dysfunction
Study: NCT01818024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single IV dose of GSK2862277
Description: GSK2862277 solution available in a 40 mg vial for IV administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo single dose IV infusion
Description: Matching placebo solution available for IV administration.
Study: NCT00696150

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: determination of method with highest efficacy (ultrasound or nerve stimulator)
Description: Use of ultrasound to guide the insertion of anterior psoas compartment block
Study: NCT00696150

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: determination of method with highest efficacy (ultrasound or nerve stimulator)
Description: Use of ultrasound to guide the insertion of anterior psoas compartment block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve stimulator
Description: The use of the nerve stimulator to guide insertion of the anterior psoas compartment block
Study: NCT01818024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single IH dose of GSK2862277
Description: GSK2862277 nebulised solution available in a 40 mg vial for IH administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo single dose IH
Description: Matching placebo nebulised solution available for IH administration.
Study: NCT00696150

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: loss of resistance
Description: Use of ultrasound to guide the insertion of anterior psoas compartment block
Study: NCT01818024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repeat IV dose of GSK2862277
Description: GSK2862277 solution available in a 40 mg vial for IV administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo repeat dose IV infusion
Description: Matching placebo solution available for IV administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repeat IH dose selected of GSK2862277 from Part 2
Description: GSK2862277 nebulised solution available in a 40 mg vial for IH administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo repeat dose IH
Description: Matching placebo nebulised solution available for IH administration.
Study: NCT03407677

Intervention type: DEVICE
Group type: OTHER
Intervention: ROTO track®
Description: An electronic injection form and injection log for keeping track of injection sites in the abdominal region. The device attaches directly to the insulin pen and activates whenever the insulin pen is picked up.
Study: NCT01885117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIVf
Description: Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIVf
Description: Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
Study: NCT04380181

Intervention type: DRUG
Intervention: dobu
Description: Use of dobutamine versus milrinone and epinephrine for separation from cardiopulmonary bypass
Study: NCT00865644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% Cream
Description: Applied topically to three tumors 5 times per week for a full 6 weeks
Study: NCT03262701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide Gel, 13 weeks
Description: 13 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide Gel, 26 weeks
Description: 26 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.

Intervention type: OTHER
Group type: OTHER
Intervention: Scaling and Root planing group
Description: Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without custom tray application of 1.7% peroxide gel
Study: NCT03903796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10234
Description: Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
Study: NCT00249561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery by Choice
Description: The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program trauma informed and trauma sensitive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Intensive Outpatient Program (IOP)
Description: The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg \& Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
Study: NCT02220881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mold making silicone toe separator
Description: Each subject in the controlled receives the custom-made mold making silicone toe separator made by certified orthotist and the recommendation of use the proper shoes without determination of current drug use

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: The participants in this groups will be educated on how to care the hallux valgus without any intervention. The follow up will be on the 3rd, 6th, 9th and 12th month.
Study: NCT01673061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: See associated Arm Description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vapocoolant
Description: See associated Arm Description
Study: NCT00707577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based maintenance program
Description: The Be Fit maintenance program is a randomized controlled trial of a 9 month intervention to maintain weight loss and physical activity after completion of the 12 week wellness program. Six teams of 25 participants will be randomized to the intervention or to usual care. There are 2 key elements to the maintenance program: personal contact and Internet contact. The personal contact enables the participants to continue receiving face-to-face support from a Be Fit nutritionist and trainer. The Internet interface is an opportunity for the participants to self-monitor their own progress while still under the guidance of the program.
Study: NCT02803216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard triple region
Description: ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard triple region
Description: ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard triple region
Description: ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-week Xiang-sha-liu-jun decoction
Description: 2-week Xiang-sha-liu-jun decoction, bid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-week Xiang-sha-liu-jun decoction
Description: 4-week Xiang-sha-liu-jun decoction, bid.
Study: NCT01187225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen concentrate
Description: In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive fibrinogen concentrate (60 mg/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive cryoprecipiate (10 ml/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
Study: NCT00101088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02278978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF1120
Description: BIBF1120 200 mg two times per day orally
Study: NCT04403204

Intervention type: OTHER
Intervention: Immunofluorescence Imaging
Description: Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.

Intervention type: OTHER
Intervention: Immunofluorescence Imaging
Description: Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.

Intervention type: OTHER
Intervention: DCE-MRI
Description: Characterize the relationship between bone perfusion as quantified by ICG based DCE-FI and DCE-MRI in human patients to develop an accurate depth-sensitive fluorescence imaging model that will correct for the surface-weighted feature of fluorescence imaging
Study: NCT02944071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter
Study: NCT01926392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: water-soluble therapy
Description: The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: water-soluble therapy
Description: The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silver sulfadiazine
Description: The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silver sulfadiazine
Description: The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
Study: NCT04601909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FX-322
Description: active comparator
Study: NCT03903796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10234
Description: Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HS-10234
Description: Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily
Study: NCT03857711

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CABG
Description: Coronary artery bypass grafting
Study: NCT02278978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF1120
Description: BIBF1120 200 mg two times per day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF1120
Description: BIBF1120 200 mg two times per day orally
Study: NCT04036565

Intervention type: BEHAVIORAL
Intervention: sunlight therapy
Description: Exposed to sunlight for at least 30 minutes per day, at least 14 days of exposure duration of 4 weeks.
Study: NCT03436589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indiana SNAP-Ed
Description: First four Indiana SNAP-Ed nutrition education lessons served as the intervention
Study: NCT03306147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain education with follow up encounters
Description: Patient pain review, counseling and education by pharmacists and physicians in follow up encounters
Study: NCT03721328

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: vancomycin hydrochloride and tobramycin sulfate
Description: vancomycin hydrochloride and tobramycin sulfate via local irrigation
Study: NCT03857711

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG+ PVI
Description: CABG+ prophylactic epicardial bipolar radiofrequency isolation of the pulmonary veins
Study: NCT01733329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
Study: NCT03484533

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV self-test kit
Description: We will conduct a randomized trial to evaluate whether provision of oral HIV self-test kits to HIV-positive pregnant women overcomes their male partners' reluctance to be tested in PMTCT clinics. Pregnant women who are randomized to the HIVST arm will be trained in the use and interpretation of HIVST, and given two oral fluid-based HIVST kits to use with or give to their partners, along with information about HIV testing and prevention and care services. We will offer men confirmatory testing regardless of their HIV test result through HIVST, counseling, and if negative, PrEP and if positive, ART.
Study: NCT03857711

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG+ PVI+amiodarone
Description: CABG+PVI+amiodarone (CABG+RFA + class III antiarrhythmic drug- amiodarone)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG+amiodarone
Study: NCT03826433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral iv
Description: 6\*10\^7 cells
Study: NCT03484533

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: In the standard of care arm, we will give women invitation letters to deliver to their male partners to come to the ANC clinic for fast-tracked HIV testing. We will offer men counseling and if negative, PrEP and if positive, ART.
Study: NCT01153490

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Intervention
Description: Substance-related

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Substance-related
Study: NCT04538950

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/CT
Description: Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.